The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
Michael L Riordan Started Gilead Sciences in 1987: Nasdaq article "Gilead Sci...WallStreetHistory
"In 1987, Michael L Riordan, at age 29, started a small biotech firm and then raised $20 million in venture capital and private equity financing, paving the way for an IPO in 1992."
Article by Tyler Laundon.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
This document discusses mergers and acquisitions in the Indian pharmaceutical industry. It defines mergers and acquisitions, provides examples of each, and compares their key differences. Mergers allow two companies to combine operations on an equal basis, while acquisitions involve one company purchasing another. The document also summarizes some major mergers and acquisitions in the industry, including GlaxoSmithKline and Lupin's acquisition of GAVIS Pharmaceuticals in 2015, which expanded Lupin's presence in the US market. Regulatory frameworks governing mergers and acquisitions in India are also outlined.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
The global market for resistant maltodextrin is expected to grow from $ 334.4 million in 2021 to $ 449.7 million in 2026. The market is expected to grow at a CAGR of 6.1% over the forecast period (2021-2026). Some of the market's key participants are Bailong Chuangyuan, Matsutani (ADM), Roquette, Tate & Lyle. This report intends to identify significant growth areas and to explore relevant market strategies. This in-depth analysis delves into the global market for resistant maltodextrin. The primary goal of this research is to examine the potential growth areas, significant trends, and the market's impact on the industry. The report also reviews the adoption of resistant maltodextrin in both established and emerging markets.
The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
Michael L Riordan Started Gilead Sciences in 1987: Nasdaq article "Gilead Sci...WallStreetHistory
"In 1987, Michael L Riordan, at age 29, started a small biotech firm and then raised $20 million in venture capital and private equity financing, paving the way for an IPO in 1992."
Article by Tyler Laundon.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
This document discusses mergers and acquisitions in the Indian pharmaceutical industry. It defines mergers and acquisitions, provides examples of each, and compares their key differences. Mergers allow two companies to combine operations on an equal basis, while acquisitions involve one company purchasing another. The document also summarizes some major mergers and acquisitions in the industry, including GlaxoSmithKline and Lupin's acquisition of GAVIS Pharmaceuticals in 2015, which expanded Lupin's presence in the US market. Regulatory frameworks governing mergers and acquisitions in India are also outlined.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
The global market for resistant maltodextrin is expected to grow from $ 334.4 million in 2021 to $ 449.7 million in 2026. The market is expected to grow at a CAGR of 6.1% over the forecast period (2021-2026). Some of the market's key participants are Bailong Chuangyuan, Matsutani (ADM), Roquette, Tate & Lyle. This report intends to identify significant growth areas and to explore relevant market strategies. This in-depth analysis delves into the global market for resistant maltodextrin. The primary goal of this research is to examine the potential growth areas, significant trends, and the market's impact on the industry. The report also reviews the adoption of resistant maltodextrin in both established and emerging markets.
From Startup to Blue Chip: The Success Story of Gilead Sciences Inc.RobertsDissertation
Gilead Sciences is a biotechnology company founded in 1987 that focuses on antiviral drugs and therapies for HIV, hepatitis B, and influenza. It took several years of operating at a loss through research and development before Gilead obtained its first private financing in 1991 and went public in 1992. Gilead's first drug, Vistide, received FDA approval in 1996. Tamiflu, approved in 1999, became widely used and stockpiled for flu pandemics. More recently, Gilead's drug Sovaldi for hepatitis C achieved a 90% cure rate but also faced controversy over its high $84,000 price for a full treatment. Despite this issue, Gilead has continued to succeed,
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
1. The document analyzes the rise in demand for the drug remdesivir as a COVID-19 treatment. It suggests the demand was driven more by public perception, preferences of pharmaceutical companies, and promotion rather than scientific data.
2. Key events that promoted remdesivir usage included its emergency use authorization in the US and a statement by Dr. Fauci promoting it. This led to a surge in orders and deals by pharmaceutical companies to distribute it globally despite limited evidence of its effectiveness.
3. Questions are raised about whether remdesivir's efficacy was proven given conflicting trial results, the high price paid for it, and whether remaining stocks will be used after shortages were reported in Europe.
The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann.docxchristiandean12115
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann Utterback, Robin Chapman, Gail Christian
Arizona State Unive rsity
Introduction
Valeant Pharmaceut icals International, Inc. pro -
motes itself as a multinational specialty pharmaceuti-
cal company with a diverse product portfolio focusing
on branded pharmaceuticals , branded and unbranded
generics, and over-the- counter (OTC) products special-
izing in neurology and dermatology.1 Product sales focus
on North America, Central Europe, Mexico, Brazil, and
Australia, with manufacturing sites in Canada, Brazil,
Poland, and Mexico. 2
In his 2006 me ssa ge to shareholders, Timothy
C. Tyson, then president and CEO, reflected , "In
many ways, 2006 was a life-changing year for Valeant
Pharmaceuticals. It was a challenging year-one that
certainly stretched us and tested our resolve. "3 That
was the year that Valeant lost its chairman, Robert
W. O'Leary, to cancer. Valeant would face a new set
of challenges in the fall of 2010, when it merged with
Canada's Biovail Corporation. Although Valeant even -
tually recovered fro m the loss of chairman Robert
W. O'Leary, would it be able to overcome the challenges
of the merger and strategically position itself to capture a
significant portion of the global pharmaceutical market
that was expected to reach $1.1 trillion by 2014?4
Although we give a brief history of Valeant here,
this case focuses on the Biovail merger and Valeant's
neurology division . This division manufactures
and markets products to treat Parkinson's disease
(PD), epilepsy, migraines, depression , chronic pain,
Huntington's disease , and myasthenia gravis. A central
question is whether Valeant will be able to capitalize
on an aging population's growing demand for its new
epilepsy drug, retigabine, and its other products. Also ,
due to significant restructuring efforts occurring before
and resulting from the merger, an important question
is whether the changes will yield the benefits promised
to sha~eholders ·and enable the firm to compete more
effectively. The answers to these questions and others
will influence Valeant's future success.
History
Valeant Pharmaceuticals was founded in 1960 by
Milan Panic, a Yugoslav defector. The company started
in California and was originally called Intern ational
Chemical & Nuclear Corp. (ICN) . Panic ran the
company for 43 years. 5 Initially, the company's primary
business involved chemical and drug sales, but it grew
through acquisitions of small drug companies. In 1963,
the company launched its IP0 .6
In 1970, ICN scientists discovered ribavirin, and in
1985, it received US Food and Drug Administration (FDA)
approval for the drug to be used as a treatment for lung
infections in children. As a blockbuster drug, ribavirin
powered ICN's growth and reputation for decades .7 In
later years, Panic directed ICN to promote ribavirin as
a treatment for AIDS and hepatitis C.8 During the 70s,
ri.
1. The document profiles the top ten CEOs including Jeff Bezos of Amazon, John Martin of Gilead Sciences, and John Chambers of Cisco Systems.
2. It provides a brief overview of each CEO and the company they lead, focusing on the industry, operations, size and acquisitions of the various technology, pharmaceutical and agricultural firms.
3. The CEOs represented work for major multinational corporations including Amazon, Gilead Sciences, Cisco, Allergan, Simon Property Group, Novo Nordisk, Monsanto, Valeant Pharmaceuticals, Precision Castparts and PotashCorp.
The pharmaceutical industry faced a challenging period from 2008-2012 due to numerous major drug patents expiring, resulting in $30 billion in lost annual brand drug revenue. Another peak of patent expirations is projected for 2014-2015, equal to the prior period. Growth in overall drug spending declined 1% in 2012 but is predicted to rebound to 3-4% growth in 2014, driven by new drug approvals and healthcare reform, before slowing again as generics continue to capture a larger share of prescriptions. Demonstrating the value of new drugs through real-world evidence will be important for companies to sustain pricing levels in this challenging environment.
The document provides an overview of the global and Indian pharmaceutical industries. It discusses key metrics like global sales, R&D spending, mergers and acquisitions, and future projections. The global pharmaceutical market experienced slow growth in 2012 due to many blockbuster drug patents expiring, but sales are expected to steadily increase to $895 billion by 2018. The Indian pharmaceutical market is also growing, driven by factors like increasing demand from emerging markets, greater acceptance of medical treatment, and a growing elderly population in India.
BASIC INFORMATIONEli Lilly and Company is one of the largest glo.docxgarnerangelika
Eli Lilly and Company is one of the largest global pharmaceutical companies founded in 1876. It has offices in 18 countries and sells products in 125 countries. The company generates billions in annual revenue and earnings growth. The document discusses Eli Lilly's major products, financial performance, acquisitions, partnerships, and competitive positioning in the pharmaceutical industry. It also provides an overview of the company's management, governance, and the broader industry environment.
BASIC INFORMATIONEli Lilly and Company is one of the largest glo.docxjasoninnes20
BASIC INFORMATION
Eli Lilly and Company is one of the largest global pharmaceutical companies in the world. Eli Lilly also has offices in Puerto Rico and 17 other countries, and its products are sold to about 125 countries. It was founded by Eli Lilly, a pharmacist, in 1876. Eli Lilly ’s main products include Ractopamine, Prozac, the antipsychotic drug, Zyprexa, and ADHD drugs Strattera, etc. The company’s ticker symbol is NYSE:LLY, the S&P 500 Index is the primary exchange upon which its shares are traded. In 2019, the company achieved revenue of US $ 22.319 billion, a year-on-year increase of 3.8%. Achieve continuous net operating profit was US $ 4.638 billion, a year-on-year increase of 47.2%. The current EPS (GAAP) reached 8.89 USD. I think it is time to invest and overweight stocks. Now the current stock price is 161.29 and the target stock price is 184.29 with the increasing market share and development of the pharmaceutical industry due to Covid-19.
INVESTMENT SUMMARY
"Lilly is in the early phase of an exciting period of growth for the company. The combination of strong revenue growth from our newer medicines and prudent expense control across our business enabled Lilly to invest more in our R&D pipeline and still deliver impressive earnings growth in the fourth quarter and full-year 2019," said David A. Ricks, Lilly's chairman, and CEO.
According to the DCF model, it displays the stock price can be reached 184.29. However, the stock price is 161.29 now. Our stock price estimate is higher than the S&P 500 market price(161.29), indicating that we believe that the stock is slightly undervalued. Lilly announced a definitive agreement to acquire Dermira, Inc. for approximately $1.1 billion in 2020. The acquisition will expand Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody. At the same time, Lilly's first lower-priced insulin, Insulin Lispro Injection, was made available in May 2019 at a 50 percent lower list price than Humalog. Lily also announced a global commercialization agreement to integrate DexCom, Inc. products into Lilly's personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom's continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management. And Lilly and Boehringer Ingelheim modernized their alliance to focus their combined expertise and investment on the continued development and commercialization of Jardiance in type 2 diabetes, heart failure, and chronic kidney disease. The development prospects bring the company higher market space and competitiveness.
BUSINESS DESCRIPTION
The company's core product lines include: Basaglar (Insulin Glargine), Jardiance (Engligliflozin), Trulicity (Duraglutide), Cyramza (ramucirumab), Emgality (galcanezumab), Olumiant (baricit ...
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crIndiaNotes.com
Zydus Cadila is a fully integrated healthcare company with strengths across the pharmaceutical value chain. In the recent quarter, the company's revenues grew 16% to Rs. 2288 crores and operating profit grew 38.3% to Rs. 495.87 crores. Key growth drivers include the US business which grew 56% and the company's global expansion efforts through new product filings and launches across geographies. The report recommends buying the stock with a target price of Rs. 2150 based on attractive valuation and expectations for double-digit growth from new technologies and global expansion.
Medopad Raises $25 Million in Series B FundingHilt Tatum IV
Medopad, a British startup that uses artificial intelligence to transform how patients and data relate to clinicians, raised $25 million in a Series B funding round from Bayer Pharmaceuticals' venture capital unit Leaps. The funding will allow Medopad to further develop AI projects like predicting Alzheimer's disease and scaling its partnership with Apple to include its patient monitoring app on the Apple Watch.
Founded by Dr. Michael L. Riordan in 1987, the biopharmaceutical company Gilead Sciences raised more than $400 million from the equity markets in the 1990s.
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Medical Devices: Acquisitions Driving GrowthBruce Carlson
The document summarizes key mergers and acquisitions that occurred in the medical device market in 2014 and early 2015 according to a report by Kalorama Information. Several large companies acquired other companies to expand their product portfolios and market share in response to modest revenue growth in the medical device market. Notable acquisitions included BD acquiring CareFusion, Medtronic acquiring Covidien, Zimmer acquiring Biomet, and Thermo Fisher acquiring Life Technologies. The mergers were aimed at boosting revenues through increased market presence, new technologies, and access to new markets.
Investing in Pharma Sector: Canadian Case Study (VRX)Almaz Tolymbek
This document discusses a case study of investing in the pharmaceutical sector using the Canadian company Valeant Pharmaceuticals International (VRX) as an example. It describes VRX's business model, growth strategy of acquisitions, financials, and recent problems. VRX grew quickly but took on large debts, and faced criticism over drug price hikes. While VRX recently reported earnings above expectations, its revenues continue to decline as interest expenses consume over 20% of revenues. With $28.5 billion in debt, institutional investors may need to consider cutting further losses by selling their VRX holdings.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Fundamental Call Report which will brief about Fundamental coverage of CADILA Healthcare Ltd
Tetra Bio-Pharma is a Canadian company developing cannabinoid-derived pharmaceutical drugs. Its CEO Guy Chamberland is considering next steps for building the Tetra brand and overcoming stigma around medical marijuana applications. Canada recently legalized recreational marijuana use, creating medical and recreational consumer markets as well as a pharmaceutical market for approved drugs. Tetra's strategy is to position itself in the pharmaceutical market through rigorous clinical trials and acquiring Drug Identification Numbers from Health Canada to gain physician trust and insurance reimbursement. It must accelerate brand-building plans before its first drug PPP001 is approved in 2019.
Now that 2012 is drawing to a close, it’s once again time to take a look back at a year that saw some big hits and misses for the biotech industry – and there were plenty of both!
AI Transformation Playbook: Thinking AI-First for Your BusinessArijit Dutta
I dive into how businesses can stay competitive by integrating AI into their core processes. From identifying the right approach to building collaborative teams and recognizing common pitfalls, this guide has got you covered. AI transformation is a journey, and this playbook is here to help you navigate it successfully.
From Startup to Blue Chip: The Success Story of Gilead Sciences Inc.RobertsDissertation
Gilead Sciences is a biotechnology company founded in 1987 that focuses on antiviral drugs and therapies for HIV, hepatitis B, and influenza. It took several years of operating at a loss through research and development before Gilead obtained its first private financing in 1991 and went public in 1992. Gilead's first drug, Vistide, received FDA approval in 1996. Tamiflu, approved in 1999, became widely used and stockpiled for flu pandemics. More recently, Gilead's drug Sovaldi for hepatitis C achieved a 90% cure rate but also faced controversy over its high $84,000 price for a full treatment. Despite this issue, Gilead has continued to succeed,
Rem de sivir - a classic analysis of desperate measures during desperate timesDr Siddharth Dutta
1. The document analyzes the rise in demand for the drug remdesivir as a COVID-19 treatment. It suggests the demand was driven more by public perception, preferences of pharmaceutical companies, and promotion rather than scientific data.
2. Key events that promoted remdesivir usage included its emergency use authorization in the US and a statement by Dr. Fauci promoting it. This led to a surge in orders and deals by pharmaceutical companies to distribute it globally despite limited evidence of its effectiveness.
3. Questions are raised about whether remdesivir's efficacy was proven given conflicting trial results, the high price paid for it, and whether remaining stocks will be used after shortages were reported in Europe.
The document discusses the growth of the global generics market from 1998-2008. It notes that major pharmaceutical companies are increasingly entering the generics market as the patents on many brand-name drugs expire. This has led to consolidation in the generics industry as large companies acquire smaller generics producers. The generics market is also shifting production to countries like India and Southeast Asia to take advantage of lower manufacturing costs.
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann.docxchristiandean12115
Jason Arnold, Kari Froehlich, Mat McBride, Stanley Parker, Ann Utterback, Robin Chapman, Gail Christian
Arizona State Unive rsity
Introduction
Valeant Pharmaceut icals International, Inc. pro -
motes itself as a multinational specialty pharmaceuti-
cal company with a diverse product portfolio focusing
on branded pharmaceuticals , branded and unbranded
generics, and over-the- counter (OTC) products special-
izing in neurology and dermatology.1 Product sales focus
on North America, Central Europe, Mexico, Brazil, and
Australia, with manufacturing sites in Canada, Brazil,
Poland, and Mexico. 2
In his 2006 me ssa ge to shareholders, Timothy
C. Tyson, then president and CEO, reflected , "In
many ways, 2006 was a life-changing year for Valeant
Pharmaceuticals. It was a challenging year-one that
certainly stretched us and tested our resolve. "3 That
was the year that Valeant lost its chairman, Robert
W. O'Leary, to cancer. Valeant would face a new set
of challenges in the fall of 2010, when it merged with
Canada's Biovail Corporation. Although Valeant even -
tually recovered fro m the loss of chairman Robert
W. O'Leary, would it be able to overcome the challenges
of the merger and strategically position itself to capture a
significant portion of the global pharmaceutical market
that was expected to reach $1.1 trillion by 2014?4
Although we give a brief history of Valeant here,
this case focuses on the Biovail merger and Valeant's
neurology division . This division manufactures
and markets products to treat Parkinson's disease
(PD), epilepsy, migraines, depression , chronic pain,
Huntington's disease , and myasthenia gravis. A central
question is whether Valeant will be able to capitalize
on an aging population's growing demand for its new
epilepsy drug, retigabine, and its other products. Also ,
due to significant restructuring efforts occurring before
and resulting from the merger, an important question
is whether the changes will yield the benefits promised
to sha~eholders ·and enable the firm to compete more
effectively. The answers to these questions and others
will influence Valeant's future success.
History
Valeant Pharmaceuticals was founded in 1960 by
Milan Panic, a Yugoslav defector. The company started
in California and was originally called Intern ational
Chemical & Nuclear Corp. (ICN) . Panic ran the
company for 43 years. 5 Initially, the company's primary
business involved chemical and drug sales, but it grew
through acquisitions of small drug companies. In 1963,
the company launched its IP0 .6
In 1970, ICN scientists discovered ribavirin, and in
1985, it received US Food and Drug Administration (FDA)
approval for the drug to be used as a treatment for lung
infections in children. As a blockbuster drug, ribavirin
powered ICN's growth and reputation for decades .7 In
later years, Panic directed ICN to promote ribavirin as
a treatment for AIDS and hepatitis C.8 During the 70s,
ri.
1. The document profiles the top ten CEOs including Jeff Bezos of Amazon, John Martin of Gilead Sciences, and John Chambers of Cisco Systems.
2. It provides a brief overview of each CEO and the company they lead, focusing on the industry, operations, size and acquisitions of the various technology, pharmaceutical and agricultural firms.
3. The CEOs represented work for major multinational corporations including Amazon, Gilead Sciences, Cisco, Allergan, Simon Property Group, Novo Nordisk, Monsanto, Valeant Pharmaceuticals, Precision Castparts and PotashCorp.
The pharmaceutical industry faced a challenging period from 2008-2012 due to numerous major drug patents expiring, resulting in $30 billion in lost annual brand drug revenue. Another peak of patent expirations is projected for 2014-2015, equal to the prior period. Growth in overall drug spending declined 1% in 2012 but is predicted to rebound to 3-4% growth in 2014, driven by new drug approvals and healthcare reform, before slowing again as generics continue to capture a larger share of prescriptions. Demonstrating the value of new drugs through real-world evidence will be important for companies to sustain pricing levels in this challenging environment.
The document provides an overview of the global and Indian pharmaceutical industries. It discusses key metrics like global sales, R&D spending, mergers and acquisitions, and future projections. The global pharmaceutical market experienced slow growth in 2012 due to many blockbuster drug patents expiring, but sales are expected to steadily increase to $895 billion by 2018. The Indian pharmaceutical market is also growing, driven by factors like increasing demand from emerging markets, greater acceptance of medical treatment, and a growing elderly population in India.
BASIC INFORMATIONEli Lilly and Company is one of the largest glo.docxgarnerangelika
Eli Lilly and Company is one of the largest global pharmaceutical companies founded in 1876. It has offices in 18 countries and sells products in 125 countries. The company generates billions in annual revenue and earnings growth. The document discusses Eli Lilly's major products, financial performance, acquisitions, partnerships, and competitive positioning in the pharmaceutical industry. It also provides an overview of the company's management, governance, and the broader industry environment.
BASIC INFORMATIONEli Lilly and Company is one of the largest glo.docxjasoninnes20
BASIC INFORMATION
Eli Lilly and Company is one of the largest global pharmaceutical companies in the world. Eli Lilly also has offices in Puerto Rico and 17 other countries, and its products are sold to about 125 countries. It was founded by Eli Lilly, a pharmacist, in 1876. Eli Lilly ’s main products include Ractopamine, Prozac, the antipsychotic drug, Zyprexa, and ADHD drugs Strattera, etc. The company’s ticker symbol is NYSE:LLY, the S&P 500 Index is the primary exchange upon which its shares are traded. In 2019, the company achieved revenue of US $ 22.319 billion, a year-on-year increase of 3.8%. Achieve continuous net operating profit was US $ 4.638 billion, a year-on-year increase of 47.2%. The current EPS (GAAP) reached 8.89 USD. I think it is time to invest and overweight stocks. Now the current stock price is 161.29 and the target stock price is 184.29 with the increasing market share and development of the pharmaceutical industry due to Covid-19.
INVESTMENT SUMMARY
"Lilly is in the early phase of an exciting period of growth for the company. The combination of strong revenue growth from our newer medicines and prudent expense control across our business enabled Lilly to invest more in our R&D pipeline and still deliver impressive earnings growth in the fourth quarter and full-year 2019," said David A. Ricks, Lilly's chairman, and CEO.
According to the DCF model, it displays the stock price can be reached 184.29. However, the stock price is 161.29 now. Our stock price estimate is higher than the S&P 500 market price(161.29), indicating that we believe that the stock is slightly undervalued. Lilly announced a definitive agreement to acquire Dermira, Inc. for approximately $1.1 billion in 2020. The acquisition will expand Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody. At the same time, Lilly's first lower-priced insulin, Insulin Lispro Injection, was made available in May 2019 at a 50 percent lower list price than Humalog. Lily also announced a global commercialization agreement to integrate DexCom, Inc. products into Lilly's personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom's continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management. And Lilly and Boehringer Ingelheim modernized their alliance to focus their combined expertise and investment on the continued development and commercialization of Jardiance in type 2 diabetes, heart failure, and chronic kidney disease. The development prospects bring the company higher market space and competitiveness.
BUSINESS DESCRIPTION
The company's core product lines include: Basaglar (Insulin Glargine), Jardiance (Engligliflozin), Trulicity (Duraglutide), Cyramza (ramucirumab), Emgality (galcanezumab), Olumiant (baricit ...
Hem recommend this pharma scrip on Q4FY15 operating profits of Rs495.87crIndiaNotes.com
Zydus Cadila is a fully integrated healthcare company with strengths across the pharmaceutical value chain. In the recent quarter, the company's revenues grew 16% to Rs. 2288 crores and operating profit grew 38.3% to Rs. 495.87 crores. Key growth drivers include the US business which grew 56% and the company's global expansion efforts through new product filings and launches across geographies. The report recommends buying the stock with a target price of Rs. 2150 based on attractive valuation and expectations for double-digit growth from new technologies and global expansion.
Medopad Raises $25 Million in Series B FundingHilt Tatum IV
Medopad, a British startup that uses artificial intelligence to transform how patients and data relate to clinicians, raised $25 million in a Series B funding round from Bayer Pharmaceuticals' venture capital unit Leaps. The funding will allow Medopad to further develop AI projects like predicting Alzheimer's disease and scaling its partnership with Apple to include its patient monitoring app on the Apple Watch.
Founded by Dr. Michael L. Riordan in 1987, the biopharmaceutical company Gilead Sciences raised more than $400 million from the equity markets in the 1990s.
Vivos Inc. is developing RadioGel, a next-generation radiopharmaceutical device to treat cancer. The company plans to generate near-term revenue from veterinary clinics and international licensing while pursuing FDA approval for multiple human cancer indications. RadioGel consists of yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies at body temperature. Vivos expects to begin sales to private veterinary clinics in 2018 and obtain international licensing revenue. The company is led by an experienced management team and advised by world-class medical and scientific boards regarding FDA approval and expanding RadioGel's applications to additional cancer types.
Medical Devices: Acquisitions Driving GrowthBruce Carlson
The document summarizes key mergers and acquisitions that occurred in the medical device market in 2014 and early 2015 according to a report by Kalorama Information. Several large companies acquired other companies to expand their product portfolios and market share in response to modest revenue growth in the medical device market. Notable acquisitions included BD acquiring CareFusion, Medtronic acquiring Covidien, Zimmer acquiring Biomet, and Thermo Fisher acquiring Life Technologies. The mergers were aimed at boosting revenues through increased market presence, new technologies, and access to new markets.
Investing in Pharma Sector: Canadian Case Study (VRX)Almaz Tolymbek
This document discusses a case study of investing in the pharmaceutical sector using the Canadian company Valeant Pharmaceuticals International (VRX) as an example. It describes VRX's business model, growth strategy of acquisitions, financials, and recent problems. VRX grew quickly but took on large debts, and faced criticism over drug price hikes. While VRX recently reported earnings above expectations, its revenues continue to decline as interest expenses consume over 20% of revenues. With $28.5 billion in debt, institutional investors may need to consider cutting further losses by selling their VRX holdings.
The best stock broker and share broker in India, Rudra Shares & Stock Brokers Ltd. is member of all the leading Equity & commodity exchanges in India, dealing in stocks, shares, commodity & currency serving clientele in 18 states through 225 business partners. Rudra Shares Fundamental Call Report which will brief about Fundamental coverage of CADILA Healthcare Ltd
Tetra Bio-Pharma is a Canadian company developing cannabinoid-derived pharmaceutical drugs. Its CEO Guy Chamberland is considering next steps for building the Tetra brand and overcoming stigma around medical marijuana applications. Canada recently legalized recreational marijuana use, creating medical and recreational consumer markets as well as a pharmaceutical market for approved drugs. Tetra's strategy is to position itself in the pharmaceutical market through rigorous clinical trials and acquiring Drug Identification Numbers from Health Canada to gain physician trust and insurance reimbursement. It must accelerate brand-building plans before its first drug PPP001 is approved in 2019.
Now that 2012 is drawing to a close, it’s once again time to take a look back at a year that saw some big hits and misses for the biotech industry – and there were plenty of both!
Similar to Gilead Sciences: First 15 Years | Article by Funding Universe (20)
AI Transformation Playbook: Thinking AI-First for Your BusinessArijit Dutta
I dive into how businesses can stay competitive by integrating AI into their core processes. From identifying the right approach to building collaborative teams and recognizing common pitfalls, this guide has got you covered. AI transformation is a journey, and this playbook is here to help you navigate it successfully.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
High-Quality IPTV Monthly Subscription for $15advik4387
Experience high-quality entertainment with our IPTV monthly subscription for just $15. Access a vast array of live TV channels, movies, and on-demand shows with crystal-clear streaming. Our reliable service ensures smooth, uninterrupted viewing at an unbeatable price. Perfect for those seeking premium content without breaking the bank. Start streaming today!
https://rb.gy/f409dk
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART KALYAN CHART
63662490260Kalyan chart, satta matta matka 143, satta matka jodi fix , matka boss OTC 420, Indian Satta, India matka, matka ank, spbossmatka, online satta matka game play, live satta matka results, fix fix fix satta namber, free satta matka games, Kalyan matka jodi chart, Kalyan weekly final anl matka 420
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Cover Story - China's Investment Leader - Dr. Alyce SUmsthrill
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
L'indice de performance des ports à conteneurs de l'année 2023SPATPortToamasina
Une évaluation comparable de la performance basée sur le temps d'escale des navires
L'objectif de l'ICPP est d'identifier les domaines d'amélioration qui peuvent en fin de compte bénéficier à toutes les parties concernées, des compagnies maritimes aux gouvernements nationaux en passant par les consommateurs. Il est conçu pour servir de point de référence aux principaux acteurs de l'économie mondiale, notamment les autorités et les opérateurs portuaires, les gouvernements nationaux, les organisations supranationales, les agences de développement, les divers intérêts maritimes et d'autres acteurs publics et privés du commerce, de la logistique et des services de la chaîne d'approvisionnement.
Le développement de l'ICPP repose sur le temps total passé par les porte-conteneurs dans les ports, de la manière expliquée dans les sections suivantes du rapport, et comme dans les itérations précédentes de l'ICPP. Cette quatrième itération utilise des données pour l'année civile complète 2023. Elle poursuit le changement introduit l'année dernière en n'incluant que les ports qui ont eu un minimum de 24 escales valides au cours de la période de 12 mois de l'étude. Le nombre de ports inclus dans l'ICPP 2023 est de 405.
Comme dans les éditions précédentes de l'ICPP, la production du classement fait appel à deux approches méthodologiques différentes : une approche administrative, ou technique, une méthodologie pragmatique reflétant les connaissances et le jugement des experts ; et une approche statistique, utilisant l'analyse factorielle (AF), ou plus précisément la factorisation matricielle. L'utilisation de ces deux approches vise à garantir que le classement des performances des ports à conteneurs reflète le plus fidèlement possible les performances réelles des ports, tout en étant statistiquement robuste.
Efficient PHP Development Solutions for Dynamic Web ApplicationsHarwinder Singh
Unlock the full potential of your web projects with our expert PHP development solutions. From robust backend systems to dynamic front-end interfaces, we deliver scalable, secure, and high-performance applications tailored to your needs. Trust our skilled team to transform your ideas into reality with custom PHP programming, ensuring seamless functionality and a superior user experience.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART INDIA MATKA KALYAN SATTA MATKA 420 INDIAN MATKA SATTA KING MATKA FIX JODI FIX FIX FIX SATTA NAMBAR MATKA INDIA SATTA BATTA
Discover the Beauty and Functionality of The Expert Remodeling Serviceobriengroupinc04
Unlock your kitchen's true potential with expert remodeling services from O'Brien Group Inc. Transform your space into a functional, modern, and luxurious haven with their experienced professionals. From layout reconfiguration to high-end upgrades, they deliver stunning results tailored to your style and needs. Visit obriengroupinc.com to elevate your kitchen's beauty and functionality today.
SATTA MATKA DPBOSS KALYAN MATKA RESULTS KALYAN CHART KALYAN MATKA MATKA RESULT KALYAN MATKA TIPS SATTA MATKA MATKA COM MATKA PANA JODI TODAY BATTA SATKA MATKA PATTI JODI NUMBER MATKA RESULTS MATKA CHART MATKA JODI SATTA COM INDIA SATTA MATKA MATKA TIPS MATKA WAPKA ALL MATKA RESULT LIVE ONLINE MATKA RESULT KALYAN MATKA RESULT DPBOSS MATKA 143 MAIN MATKA KALYAN MATKA RESULTS KALYAN CHART
Satta Matka Dpboss Kalyan Matka Results Kalyan Chart
Gilead Sciences: First 15 Years | Article by Funding Universe
1. • • •• •
Browse Company Profiles: (0-9) A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Gilead Sciences, Inc. History
Address:
333 Lakeside Drive
Foster City, California 94404
U.S.A.
Telephone: (650) 574-3000
Toll Free: 800-445-3235
Fax: (650) 578-9264
Website: www.gilead.com
Company Perspectives:
Public Company
Incorporated: 1987
Employees: 1,027
Sales: $233.80 million (2001)
Stock Exchanges: NASDAQ
Ticker Symbol: GILD
NAIC: 325414 Biological Product (Except Diagnostic)
Manufacturing; 541710 Research and Development in the
Physical, Engineering, and Life Sciences
From our inception, the people of Gilead across the United States, Europe and Australia have shared a vision of advancing
therapeutics for life-threatening diseases worldwide. As a leading biopharmaceutical company, we have been fulfilling that vision
for more than a decade--discovering, developing and commercializing small molecule therapeutics to advance the care of patients
suffering from life-threatening infectious diseases.
Key Dates:
1987: Gilead Sciences, Inc. is founded by Michael Riordan, M.D.
1992: The company completes its initial public offering of stock.
1996: The FDA approves the sale of Vistide.
1999: Gilead acquires NeXstar Pharmaceuticals, Inc.
2001: Gilead receives FDA approval for Viread, an HIV treatment drug.
2002: Gilead announces that it will acquire Triangle Pharmaceuticals, Inc.
Company History:
Gilead Sciences, Inc. is a biotechnology company specializing in developing and marketing drugs to treat antiviral diseases.
Gilead's primary focus is in developing treatments for the human immunodeficiency virus (HIV),a virus that causes acquired
immune deficiency syndrome (AIDS)and infections related to AIDS. The company markets Vistide, used to treat eye infections, and
Viread, an HIV treatment. Aside from its work related to HIV and AIDS, Gilead also markets a drug to treat the flu, a pharmaceutical
marketed by the company as Tamiflu, and a drug to treat fungal infections, which is marketed under the name AmBisome.
Origins
Gilead drew its strategic focus from its founder, Michael Riordan. Riordan, who started Gilead when he was 29 years old, earned
his medical degrees from Johns Hopkins University and Harvard. With his degrees in hand, Riordan entered the realm of finance, a
seemingly incongruent career choice that proved indispensable to Gilead's financial well-being. Riordan spent a year working for
Menlo Ventures, learning the vagaries of venture capitalism. As his success in finding funding for Gilead would reflect, Riordan
proved to be an adept venture capitalist. Gilead, as a pharmaceutical developer, would require substantial amounts of capital to
finance its research, capital that could not be recouped for years, perhaps even decades. Riordan directed the company's
research toward the discovery of drugs designed to cure or to mitigate the effects of viral diseases, particularly sexually
transmitted diseases (STDs), and notably the most notorious of all STDs, HIV.For the name of his company, Riordan drew his
inspiration from the history of the ancient Middle East, where a region known as Gilead gained recognition for a medication called
the balm of Gilead, considered the world's first genuine pharmaceutical product.
2. Riordan founded Gilead in June 1987. The following year he raised $2 million from his venture capitalist sources. With the infusion
of capital, Riordan moved the company to Foster City, California, where Gilead scientists focused their efforts on developing
pharmaceuticals to fight viral diseases, cardiovascular disease, and cancer. The company's research centered on what were
known as "anti-sense" drugs, which were believed to have the potential to block the genetic messages that trigger disease. The
field was promising but, like all business pursuits characterized as promising, the financial rewards were speculative. Riordan was
gambling on future discoveries and future rewards.
In 1989, a year after Riordan raised $2 million to finance Gilead's relocation to Foster City, he succeeded in raising $10 million in
venture capital. Gilead did not generate any revenues, as expected, until the end of its fiscal year in March 1991. For the year, the
company collected $1.3 million in revenue, but the first-time gross was offset by a $4 million loss. Financially, Gilead's progress
was bleak during its formative decade of existence. The company posted annual losses consistently, but the red ink did not
dissuade venture capitalists from banking on the promise of Gilead's pharmaceutical discoveries gaining entry into the market. In
September 1991, Riordan secured $20 million in private equity financing, bolstering Gilead's research and development coffers.
The $20 million private placement was part of the more than $40 million Riordan secured from financial institutions, a figure that
included funds received from the company's partnership with the respected $3.5 billion English drug conglomerate Glaxo Holdings
PLC. From Glaxo, Gilead received $8 million to develop genetic code-blockers to combat cancer.
Several months after securing $20 million in private equity financing, Riordan began preparing for Gilead's debut in the public
spotlight. In December 1991, the company filed with the Securities and Exchange Commission for its initial public offering {IPO).
The IPO was slated to be completed in January 1992, at which point the company hoped to raise $42 million. As Riordan prepared
to turn to Wall Street as a source of research and development capital, Gilead scientists were hard at work developing small
molecule antiviral therapeutics, research that was based on nucleotide compounds that had been licensed from two European
academic laboratories. Toward the end of January 1992, Gilead completed its IPO, an offering that resulted in $86.25 million in
proceeds. The investing public appeared willing to take a gamble on Gilead's future success. Gilead's IPO would not be the last
time Riordan turned to Wall Street for cash.
Roughly six months after Gilead's debut on the NASDAQ, the company had yet to introduce a pharmaceutical product. Instead,
revenue was derived from research and development projects conducted in partnership with other parties. The company's work to
combat cancer, undertaken at the behest of Glaxo, represented one such project. By mid-1992, the company also was working on
a program tied to the U.S. Defense Department's Advanced Research Projects Agency. Under the specifications of the project,
Gilead scientists were charged with developing drugs to combat malaria, Dengue fever, and other tropical diseases. Of particular
importance during this juncture of the company's history was its work on CMV retinitis, an AIDS-related eye disease. During the
first half of 1992, Gilead filed an investigational new drug application with the U.S. Food and Drug Administration {FDA)covering a
compound, cidofovir injection, for the treatment for CMV retinitis. The compound was branded as Vistide by Gilead, a product that
would figure prominently in the company's future.
In 1995, after waiting eight years and spending $93.3 million on drug research and development, Gilead was ready to introduce its
first product on the market. The company applied to the FDA for approval of Vistide in October 1995, which, when approved by the
FDA, would thrust Gilead into a market estimated to be worth $150 million in annual revenue. In December 1995, the company
submitted an equivalent application to the European Medicines Evaluation Agency. Vistide, according to the company's claims,
represented a breakthrough, one that potentially could increase the size of the CMV retinitis market. Unlike the other treatments
available on the market, foscarnet and ganciclovir, which required surgically inserted catheters, Vistide was administered
intravenously. His long wait nearly over, Riordan hoped to obtain FDA approval within six months, setting the stage for Vistide's
debut in the U.S. market for late 1996.
As expectations rose for the introduction of Vistide, Gilead had yet to generate any profits. During fiscal 1995, it generated $4.9
million in revenue thanks to its collaborative relationship with Glaxo, but otherwise the financial highlights of Gilead's first eight
years of business were nonexistent. Despite the seemingly precarious position held by Gilead, Riordan found himself surrounded
by money. A secondary public offering in August 1995 raised $94.2 million, giving the company's founder and chief executive
officer nearly $160 million to use to market Vistide and Gilead's other antiviral drugs.
3. 1996: The Debut of Vistide
As Gilead braced itself for the market introduction of Vistide and while it tended to the development of the other drugs in its
portfolio, the desire for additional cash did not abate. In February 1996, the company completed its fourth public offering, issuing
four million shares of stock that yielded net proceeds of $162.5 million. The stockpiled financial resources found expression in
June 1996, when the FDA gave its nod of approval. The federal agency gave its approval of Vistide's use for the treatment of CMV
retinitis in patients suffering from AIDS, triggering a quick response from Gilead's Roster City headquarters. Within hours of the
FDA's approval, the company began shipping Vistide to wholesaler and specialty distributors nationwide, with sales spearheaded
by a network of agents Gilead referred to as "Antiviral Specialists. 11
One month later, the company prepared for a similar rollout of
Vistide in foreign markets, signing an agreement with pharmaceutical giant Pharmacia & Upjohn to market the AIDs-related
blindness drug in all markets outside the United States.
During the latter half of the 1990s, Gilead's legitimacy as a drug developer increased, as its claims of possessing drugs of valuable
efficacy proved themselves on the market. The company grabbed the headlines at the end of the decade when it announced the
acquisition of a much larger company. In March 1999, the company revealed its plan to acquire Boulder, Colorado-based NeXstar
Pharmaceuticals Inc., a company whose 1998 sales volume of $130 million was three times Gilead's total for the year. The
proposed merger, reportedly, was the result of two years of negotiations, stemming from discussions held between Gilead and
NeXstar officials that had begun in April 1997. For its part, NeXstar wanted to consummate the merger because the company had
decided against evolving into a full-fledged pharmaceutical company. By completing the merger, NeXstar's biochemistry scientists
would be free to focus on science, cut free from the distractions of dealing with federal regulators, the demands of Wall Street, and
the concerns of delivering financial figures to appease others. Gilead, willing to accept the responsibilities of operating as a full-
fledged pharmaceutical company, desired NeXstar's two revenue-generating drugs, a fungal treatment marketed as AmBisome
and an anti-cancer agent used by AIDS patients marketed as DaunoXome. Sweetening the pot for Gilead was NeXstar's European
and Australian sales force, which would prove useful as the company exerted itself as an international drug developer and
marketer.
Rapid Sales Growth During the Late 1990s
As Gilead exited the 1990s and entered the 21st century, its revenues increased at a fantastic rate. Between 1998 and 2001, the
company's sales increased 501 percent, pushed upward by the growing popularity of Gilead's portfolio of pharmaceuticals.
Leading the pack was AmBisome, the injectable antifungal medication that the company gained through the NeXstar merger.
AmBisome generated $142 million in sales in 2000. Two other drugs, Vistide and Tamiflu, an influenza treatment, also were gaining
market share, helping to drive the company's sales upward. Looking ahead, Gilead executives were excited by the revenue
generating potential of a new drug. In May 2001, the company applied for FDA market approval of Tenofovir DF,an oral tablet that
blocked reverse transcriptase, an enzyme crucial to the replication of HIV. Expectations for Tenofovir's market success were high,
both inside and outside the company. In a May 25, 2001 interview with the San Francisco Business Times, a pharmaceutical
analyst remarked, "Tenofovir has the potential to generate annual sales of more than $100 million, which could make Gilead
profitable in 2002. 11
As its 15th anniversary approached, Gilead sharpened its focus on its expertise in infectious diseases. In November 2001, the
company received FDA approval for a new HIV treatment drug it named Viread. Later in the month, the company sold its oncology
business to OSI Pharmaceuticals, Inc. for approximately $170 million, shedding its involvement in developing drugs to treat cancer
so more attention could be paid to infectious diseases. At roughly the same time, the company sold the use of its technology
library to Cambridge, Massachusetts-based Archemix Corp., a two-year agreement that netted Gilead $17.5 million. In a
November 30, 2001 interview with the San Francisco Business Times, John Martin, Gilead's president and chief executive officer at
the time, remarked, "This deal is an important step for Gilead as we continue to focus on our core competence. 11
Gilead's achievements during its first 15 years of business were sufficient to ensure its place among the industry's leading
concerns. Years of research and development work, fueled by the investment of millions of dollars, had produced several
important drugs whose market appeal had delivered sizable financial rewards. The sale of the company's oncology business left it
focused exclusively on the antiviral market, providing a clear indication of which direction Gilead was pointed toward for the future.
In December 2002, the company announced an acquisition that promised to bolster its position in the antiviral market
considerably. Gilead announced that it had made a $464 million offer for Triangle Pharmaceuticals, Inc. The union of the two
companies was viewed as complementary, with Triangle's late-stage HIV candidate Coviracil and its collection of other HIV and
chronic hepatitis B therapeutics meshing well with Gilead's antiviral product portfolio. In anticipation of consummating the
acquisition, Gilead announced that it would begin developing a co-formulation of Coviracil and Viread, its HIV drug. If successful,
the result would be the first combination product dosed as one pill taken daily.
Principal Subsidiaries: Triangle Pharmaceuticals, Inc.
Principal Competitors: Bristol-Meyers Squibb Company; Merck & Co., Inc.; Shire BioChem Inc.
4. Further Reading:
• Austin, Marsha, 11
NeXstar Deal May Mark Change in Biotech Future,11
Business Journal--Serving Phoenix & The Valleyof the
Sun, February 18, 2000, p. 178.
• Doherty, Brendan, "New AIDS Drug May Be Solid Prescription for Gilead's Profitability," San Francisco Business Times, May
25, 2001, p. 53.
• Dubroff, Henry, 11
NeXstar Points Toward Biotech's Future,11
Denver Business Journal, March 5, 1999, p. 1A.
•
11
Gilead Sciences lnc., 11
Insiders• Chronicle, May 4, 1992, p. 2.
•
11
Gilead's Viread Gains FDA Approval, 11
San Francisco Business Times, November 2, 2001, p. 54.
• Ginsberg, Steve, 11
lmproving Its Vision,11
San Francisco Business Times, October 6, 1995, p. 3.
• Gorman, Christine, 11
Flu Stopper: A New Compound Is Set for Human Testing This Year,11
Time, February 10, 1997, p. 62.
• Graebner, Lynn, "Gilead in a Growth Mode, 11
Business Journal, November 19, 1999, p. 20.
•
11
OSI Pharmaceuticals Acquires Gilead Cancer Business, 11
Long Island Business News, November 30, 2001, p. 13A.
• Rauber, Chris, 11
Gilead's Offering Seeks $42 Million, 11
San Francisco Business Times, December 20, 1991, p. 1.
Source: International Directory of Company Histories, Vol. 54. St. James Press, 2003.